<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">genort</journal-id><journal-title-group><journal-title xml:lang="ru">Гений ортопедии</journal-title><trans-title-group xml:lang="en"><trans-title>Genij Ortopedii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1028-4427</issn><issn pub-type="epub">2542-131X</issn><publisher><publisher-name>ЦЕНТР ИЛИЗАРОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18019/1028-4427-2025-31-2-245-251</article-id><article-id custom-type="elpub" pub-id-type="custom">genort-3212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Диагностическое значение интерлейкина-6 и тимидинфосфорилазы в прогрессировании остеосаркомы</article-title><trans-title-group xml:lang="en"><trans-title>The diagnostic value of IL-6 and thymidine phosphorylase in the progression of osteosarcoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2370-0416</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Abdul Azeez</surname><given-names>B. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdul Azeez</surname><given-names>B. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bushra AM Abdul Azeez — MD</p></bio><bio xml:lang="en"><p>Bushra AM Abdul Azeez — MD</p></bio><email xlink:type="simple">bushra.abdulaziz@uobasrah.edu.iq</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9722-0816</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Abd Alhussain</surname><given-names>G. S.</given-names></name><name name-style="western" xml:lang="en"><surname>Abd Alhussain</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ghufran Salman Abd Alhussain — MD</p></bio><bio xml:lang="en"><p>Ghufran Salman Abd Alhussain — MD</p></bio><email xlink:type="simple">ghufrans.althabhawi@uokufa.edu.iq</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-2051-7236</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Salman</surname><given-names>R. S.</given-names></name><name name-style="western" xml:lang="en"><surname>Salman</surname><given-names>R. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Rabab Alhosainy Salman — MD</p></bio><bio xml:lang="en"><p>Rabab Alhosainy Salman — MD</p></bio><email xlink:type="simple">rababshaker@shu.edu.iq</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2108-1668</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Al-Fahham</surname><given-names>A. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Al-Fahham</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ali A. Al-Fahham — Professor</p></bio><bio xml:lang="en"><p>Ali A. Al-Fahham — Professor</p></bio><email xlink:type="simple">fahham925@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>University of Basrah</institution><country>Ирак</country></aff><aff xml:lang="en"><institution>University of Basrah</institution><country>Iraq</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>University of Kufa</institution><country>Ирак</country></aff><aff xml:lang="en"><institution>University of Kufa</institution><country>Iraq</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>University of Al-Shatrah</institution><country>Ирак</country></aff><aff xml:lang="en"><institution>University of Al-Shatrah</institution><country>Iraq</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>04</month><year>2025</year></pub-date><volume>31</volume><issue>2</issue><fpage>245</fpage><lpage>251</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Abdul Azeez B.A., Abd Alhussain G.S., Salman R.S., Al-Fahham A.A., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Abdul Azeez B.A., Abd Alhussain G.S., Salman R.S., Al-Fahham A.A.</copyright-holder><copyright-holder xml:lang="en">Abdul Azeez B.A., Abd Alhussain G.S., Salman R.S., Al-Fahham A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ilizarov-journal.com/jour/article/view/3212">https://www.ilizarov-journal.com/jour/article/view/3212</self-uri><abstract><sec><title>Введение</title><p>Введение. Тимидинфосфорилаза (ТФ) коррелирует с патогенезом солидных опухолей. Интерлейкин-6 (ИЛ-6) имеет повышенную экспрессию при остеосаркоме. Высокие концентрации ИЛ-6 дают основание предполагать плохой прогноз и агрессивный характер опухоли.</p><p>Цель работы — изучение диагностической роли ТФ и ИЛ-6 в патогенезе и прогрессировании остеосаркомы.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В текущее исследование включены 30 пациентов с диагнозом остеосаркома в возрасте от 15 до 44 лет. Пациенты распределены по стадиям AI (n = 6), BI (n = 15), II (n = 5) и III (n = 4).</p></sec><sec><title>Результаты</title><p>Результаты. Статистический анализ показал, что ИЛ-6 имеет тенденцию к повышению у пациентов на  стадии III, (3,89 ± 0,34) нг/мл, по сравнению со стадиями AI, BI и II: (1,48 ± 0,22) нг/мл, (1,55 ± 0,24) нг/мл и (2,45 ± 0,45) нг/мл. Что касается ТФ, данное исследование также показало, что она имеет тенденцию к повышению у пациентов на стадии III, (8,3 ± 0,33) нг/мл, по сравнению со стадиями AI, BI и II: (7,2 ± 0,92) нг/мл, (6,82 ± 1,14) нг/мл и (7,8 ± 0,22) нг/мл соответственно. Площадь под кривой (AUC) для ТФ составила 0,87 с высокой значимой разницей p &lt; 0,001 при точке отсечения 2,44, в то время как коэффициенты чувствительности и специфичности составили 0,85 и 0,71. Что касается ИЛ-6, площадь под кривой (AUC) составила 0,75, со значительной разницей p &lt; 0,038, при точке отсечения 6,32, в то время как коэффициенты чувствительности и специфичности составили 0,81 и 0,69 соответственно. Эти биомаркеры также можно использовать в диагностике и прогрессировании остеосаркомы.</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Высокий уровень ТФ является показателем агрессивности опухоли и плохим прогностическим фактором. Отдельные исследования посвящены экспрессии TФ на разных стадиях остеосаркомы, но их число невелико. В последнее время ТФ привлекает значительное внимание своим участием в биологии рака, особенно своим влиянием на патогенез и прогноз заболевания. Согласно исследованиям, TФ играет важную роль в развитии большинства злокачественных заболеваний, и особенно злокачественных новообразований костей. ТФ способствует ангиогенезу, экспрессируя в опухоль-ассоциированных макрофагах в строме опухоли. Экспрессия ТФ изучена при различных типах рака в качестве прогностического фактора. На основе данных литературы могут быть разработаны новые прогностические модели для пациентов с раком костей.</p></sec><sec><title>Заключение</title><p>Заключение. Активность ТФ и ИЛ-6 имеет значительную диагностическую ценность при прогрессировании остеосаркомы.</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction Thymidine phosphorylase (TP) is known to be correlated with the pathogenesis of solid tumors. IL-6 is overexpressed in osteosarcoma, and data exist showing that high concentrations of IL-6 are linked to a poor prognosis.</p><p>The aim of this study is to investigate the diagnostic role of thymidine phosphorylase and IL-6 in the pathogenesis and progression in patients with osteosarcoma.</p><p>Materials and methods Thirty patients diagnosed with osteosarcoma (with age ranging between 15–44 years) were included in the current study. Those patients were distributed as 6, 15, 5 and 4 subjects for stages AI, BI, II and III respectively.</p><p>Results Statistical analysis pointed out that IL-6 tends to be increased patients in stage III (3.89 ± 0.34 ng/ml) compared to stage AI, BI and II: 1.48 ± 0.22 ng/ml, 1.55 ± 0.24 ng/ml and 2.45 ± 0.45 ng/ml respectively. Regarding thymidine phosphorylase, the current study also found that it tends be increased patients in stage III 8.3 ± 0.33 ng/ml comparing to stage  AI, BI and II: 7.2 ± 0.92 ng/ml, 6.82 ± 1.14 ng/ml and  7.8 ± 0.22 ng/ml, respectively. The area under the curve (AUC) for thymidine phosphorylase was 0.87, with high significant difference p &lt; 0.001, at a cut-off point 2.44, while the sensitivity and specificity ratios were 0.85, and 0.71 respectively. Regarding IL-6, the area under the curve (AUC) was 0.75, with significant difference p &lt; 0.038, at  a  cut-off point 6.32, while the sensitivity and specificity ratios were 0.81, and 0.69 respectively. These biomarkers can also be used in the diagnosis and progression of osteosarcoma.</p><p>Discussion High levels of TP are expressions of tumor aggressiveness and poor prognostic factors. Some separate studies focus on TP expression at different osteosarcoma stages but their numbers are few, arguing that there is a gap in the current available literature. TP more recently has attracted significant attention for its involvement in cancer biology, especially with regard to its influence on disease pathogenesis and prognosis, according to available studies, TP plays a major part in the development of most malignant diseases, and particularly bone-related malignancies. It has been observed that TP promotes angiogenesis, is expressed in tumor-associated macrophages within the tumor stroma. TP expression has been studied in different types of cancer as a predictive body. New prognostic models for patients with bone cancer can be developed based on literature data.</p><p>Conclusion It is suggested that thymidine phosphate activity and IL-6 have a significant high diagnostic power in the diagnosis and progression of osteosarcoma.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тимидинфосфорилаза</kwd><kwd>интелейкин-6</kwd><kwd>диагностика</kwd><kwd>остеосаркома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>thymidine phosphorylase</kwd><kwd>IL-6</kwd><kwd>diagnosis power</kwd><kwd>osteosarcoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Giaquinto AN, Sung H, Miller KD, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-541. doi: 10.3322/caac.21754.</mixed-citation><mixed-citation xml:lang="en">Giaquinto AN, Sung H, Miller KD, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-541. doi: 10.3322/caac.21754.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-679. doi: 10.1182/blood-2016-10-695940.</mixed-citation><mixed-citation xml:lang="en">Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-679. doi: 10.1182/blood-2016-10-695940.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12. doi: 10.1051/sicotj/2017028.</mixed-citation><mixed-citation xml:lang="en">Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12. doi: 10.1051/sicotj/2017028.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem. 1954;207(1):245-256.</mixed-citation><mixed-citation xml:lang="en">Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem. 1954;207(1):245-256.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Iltzsch MH, el Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry. 1985;24(24):6799-807. doi: 10.1021/bi00345a011.</mixed-citation><mixed-citation xml:lang="en">Iltzsch MH, el Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry. 1985;24(24):6799-807. doi: 10.1021/bi00345a011.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6(3):158-166. doi: 10.1016/S1470-2045(05)01766-3.</mixed-citation><mixed-citation xml:lang="en">Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6(3):158-166. doi: 10.1016/S1470-2045(05)01766-3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 2009;29(6):903-953. doi: 10.1002/med.20159.</mixed-citation><mixed-citation xml:lang="en">Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 2009;29(6):903-953. doi: 10.1002/med.20159.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Stenman G, Sahlin P, Dumanski JP, et al. Regional localization of the human platelet-derived endothelial cell growth factor (ECGF1) gene to chromosome 22q13. Cytogenet Cell Genet. 1992;59(1):22-23. doi: 10.1159/000133191.</mixed-citation><mixed-citation xml:lang="en">Stenman G, Sahlin P, Dumanski JP, et al. Regional localization of the human platelet-derived endothelial cell growth factor (ECGF1) gene to chromosome 22q13. Cytogenet Cell Genet. 1992;59(1):22-23. doi: 10.1159/000133191.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fox SB, Moghaddam A, Westwood M, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol. 1995;176(2):183-190. doi: 10.1002/path.1711760212.</mixed-citation><mixed-citation xml:lang="en">Fox SB, Moghaddam A, Westwood M, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol. 1995;176(2):183-190. doi: 10.1002/path.1711760212.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Salman RS, Abdul Azeez BAM, Munshid MC, Al-Fahham AA. Inflammatory Response and Pathophysiology of IL-6 Overproduction: A Review Article. IJHMR. 2024;3(8):568-572. doi: 10.58806/ijhmr.2024.v3i08n05.</mixed-citation><mixed-citation xml:lang="en">Salman RS, Abdul Azeez BAM, Munshid MC, Al-Fahham AA. Inflammatory Response and Pathophysiology of IL-6 Overproduction: A Review Article. IJHMR. 2024;3(8):568-572. doi: 10.58806/ijhmr.2024.v3i08n05.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38-47. doi: 10.1016/j.smim.2014.01.008.</mixed-citation><mixed-citation xml:lang="en">Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38-47. doi: 10.1016/j.smim.2014.01.008.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-970. doi: 10.2217/imt-2016-0020.</mixed-citation><mixed-citation xml:lang="en">Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-970. doi: 10.2217/imt-2016-0020.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tabata S, Yamamoto M, Goto H, et al. Thymidine Catabolism as a Metabolic Strategy for Cancer Survival. Cell Rep. 2017;19(7):1313 1321. doi: 10.1016/j.celrep.2017.04.061.</mixed-citation><mixed-citation xml:lang="en">Tabata S, Yamamoto M, Goto H, et al. Thymidine Catabolism as a Metabolic Strategy for Cancer Survival. Cell Rep. 2017;19(7):1313 1321. doi: 10.1016/j.celrep.2017.04.061.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Furukawa T, Tabata S, Yamamoto M, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15-20. doi: 10.1016/j.phrs.2018.03.019.</mixed-citation><mixed-citation xml:lang="en">Furukawa T, Tabata S, Yamamoto M, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15-20. doi: 10.1016/j.phrs.2018.03.019.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Akiyama S, Furukawa T, Sumizawa T, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci. 2004;95(11):851-857. doi: 10.1111/j.1349-7006.2004.tb02193.x.</mixed-citation><mixed-citation xml:lang="en">Akiyama S, Furukawa T, Sumizawa T, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci. 2004;95(11):851-857. doi: 10.1111/j.1349-7006.2004.tb02193.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumae G, Shimizu T, Tian Y, et al. Targeting thymidine phosphorylase as a potential therapy for bone loss associated with periprosthetic osteolysis. Bioeng Transl Med. 2021;6(3):e10232. doi: 10.1002/btm2.10232.</mixed-citation><mixed-citation xml:lang="en">Matsumae G, Shimizu T, Tian Y, et al. Targeting thymidine phosphorylase as a potential therapy for bone loss associated with periprosthetic osteolysis. Bioeng Transl Med. 2021;6(3):e10232. doi: 10.1002/btm2.10232.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tang B, Xu A, Xu J, et al. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Int J Cancer. 2018;142(1):109-120. doi: 10.1002/ijc.31041.</mixed-citation><mixed-citation xml:lang="en">Tang B, Xu A, Xu J, et al. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Int J Cancer. 2018;142(1):109-120. doi: 10.1002/ijc.31041.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bitter EE, Townsend MH, Erickson R, et al. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci. 2020;10(1):138. doi: 10.1186/s13578-020-00493-1.</mixed-citation><mixed-citation xml:lang="en">Bitter EE, Townsend MH, Erickson R, et al. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci. 2020;10(1):138. doi: 10.1186/s13578-020-00493-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Elamin YY, Rafee S, Osman N, et al. Thymidine Phosphorylase in Cancer; Enemy or Friend? Cancer Microenviron. 2016;9(1):33-43. doi: 10.1007/s12307-015-0173-y.</mixed-citation><mixed-citation xml:lang="en">Elamin YY, Rafee S, Osman N, et al. Thymidine Phosphorylase in Cancer; Enemy or Friend? Cancer Microenviron. 2016;9(1):33-43. doi: 10.1007/s12307-015-0173-y.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Xu JF, Wang YP, Zhang SJ, et al. Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy. Oncotarget. 2017;8(44):75968-75978. doi: 10.18632/oncotarget.18373.</mixed-citation><mixed-citation xml:lang="en">Xu JF, Wang YP, Zhang SJ, et al. Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy. Oncotarget. 2017;8(44):75968-75978. doi: 10.18632/oncotarget.18373.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.</mixed-citation><mixed-citation xml:lang="en">Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399-409. doi: 10.1038/nrrheum.2017.83.</mixed-citation><mixed-citation xml:lang="en">Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399-409. doi: 10.1038/nrrheum.2017.83.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694-4703. doi: 10.1172/JCI138554.</mixed-citation><mixed-citation xml:lang="en">Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694-4703. doi: 10.1172/JCI138554.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579-596. doi: 10.1084/jem.20162024.</mixed-citation><mixed-citation xml:lang="en">Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579-596. doi: 10.1084/jem.20162024.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Dethlefsen C, Højfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657-664. doi: 10.1007/s10549-013-2488-z.</mixed-citation><mixed-citation xml:lang="en">Dethlefsen C, Højfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657-664. doi: 10.1007/s10549-013-2488-z.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525(7569):389-393. doi: 10.1038/nature15252.</mixed-citation><mixed-citation xml:lang="en">Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525(7569):389-393. doi: 10.1038/nature15252.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127-148. doi: 10.1093/intimm/dxaa078.</mixed-citation><mixed-citation xml:lang="en">Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127-148. doi: 10.1093/intimm/dxaa078.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
